VENUS REMEDIES
|
The Current P/E Ratio of VENUS REMEDIES is 16.50.
| Share Price | ₹939.7 | May 14,2026 |
| Market Cap | ₹1,259.2 Cr | |
| Earnings-TTM | ₹76.3 Cr | TTM-Consolidated Results |
| Price/Earnings | 16.50x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of VENUS REMEDIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,259.2 Cr] as on May 14,2026
(/) Earnings [ ₹76.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 16.50x ]
Thus, for VENUS REMEDIES , the investors are currently willing to pay 16.50 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of VENUS REMEDIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of VENUS REMEDIES over the last five years.
Historical PE (Price/Earnings) ratio chart of VENUS REMEDIES
PE Ratio Performance Analysis for VENUS REMEDIES
- VENUS REMEDIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 9.32x.
- VENUS REMEDIES 's operated at median p/e ratio of 8.82x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, VENUS REMEDIES 's p/e ratio peaked in Mar2024 at 15.31x.
- VENUS REMEDIES 's p/e ratio hit its five-year low in Mar2021 of 5.49x.
How does VENUS REMEDIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| VENUS REMEDIES | 76.31 | 16.50 | 1,259.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 40.63 | 447,032.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 74.13 | 183,759.0 |
| CIPLA LTD | 3,869.79 | 30.03 | 116,214.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 65.68 | 149,224.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 26.24 | 108,739.0 |
| MANKIND PHARMA LTD | 1,796.65 | 56.57 | 101,634.0 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 20.22 | 99,748.0 |
| LUPIN LTD | 5,355.47 | 19.28 | 103,230.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 24.96 | 87,680.7 |
| ABBOTT INDIA LTD | 1,552.02 | 37.67 | 58,468.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs VENUS REMEDIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.50x |
| Max industry PE | 74.13x |
| Median industry PE | 30.03x |
| Average industry PE | 37.45x |
You may also like the below Video Courses